← Our News

Research & clinical trials, Information & guidance, Charity news & media, For health professionals

Investing in Impact: Announcing Our First 2026 Research Grants

By Beth Chesser

Posted 7 months ago

24/04/2026 10am
Dr Tu Vinh Luong, Royal Free Hospital NHS Trust. Pump-priming grant 2026 Awardee

We are pleased to begin announcing the projects that will be funded through our 2026 research investment of £100,000. This funding has been carefully designed to support both shorter-term, practice-based improvements and longer-term innovation to enhance outcomes for people living with neuroendocrine cancer. We are really grateful for the generosity of our community in enabling us to fund this research.

This year, funding is split across two grant types. Our Practice-Changing Grants (up to £5,000) support practical projects that can deliver real-world impact within 18 months. Our Pump Priming Grants ( up to £30,000 each) fund pilot projects aimed at generating evidence to drive longer-term improvements in care and outcomes for neuroendocrine cancer.

Today, we are announcing one winner from each grant stream, with further recipients to be shared next week.

Pump-priming grant: AI-based prediction of SSTR2 expression from H&E whole-slide images in small intestinal neuroendocrine tumours (SI-NETs) with exploratory Ki-67 grade-band estimation, Dr Tu Vinh Luong, Royal Free Hospital NHS Trust, £30,000

Practice-changing grant: Should primary small intestinal neuroendocrine tumours and carcinoid heart disease surgery be performed in large or small centres? A national outcomes study using linked NCRAS–HES data to produce an implementable UK referral pathway and survival machine learning models. Mohamed Mortagy, Hampshire Hospitals Foundation Trust, £5,000

 

More info on pump priming AI:
Small bowel neuroendocrine tumours need a key test, called SSTR2 expression, to guide diagnosis and treatment. This relies on an expensive specialist scan that is not available in all hospitals, causing treatment decision delays. We aim to develop an artificial intelligence (AI) tool that analyses routine biopsy slides to estimate SSTR2 expression before the scan is done. This could help patients start appropriate treatment sooner. The study will assess how accurate, safe and practical this tool is within NHS care.
This would overcome the uncertainty that generates significant psychological burden for patients. Newly diagnosed individuals receive exhaustive counselling on multiple treatment modalities, many of which will prove inappropriate once imaging confirms receptor status. This information overload, followed by subsequent revision of management plans, may erode patient confidence, increase anxiety and necessitate additional clinical visits during an already stressful diagnostic period.

 

More info on practice changing:
Small intestinal neuroendocrine tumours (SI-NET) are a rare cancer of the small bowel. They are often diagnosed late and can be difficult to treat, with around one in four patients needing emergency surgery. Some patients also develop carcinoid heart disease, where the tumour damages the heart valves and heart surgery can be life-changing.

 

At the moment, there is no clear UK-wide guidance on where these operations should take place. Should they always be carried out in large specialist centres, or can they be done just as safely in local hospitals? The answer matters, both for patients and for how the NHS plans its services.

 

Our project will bring together England’s national cancer registry and national hospital records to look at the outcomes of SI-NET patients treated between 2012 and 2021. By comparing how patients recovered after surgery in different types of hospital, we will identify which factors most affect survival and complications.

 

This will help clinicians direct each patient to the right hospital for their operation and help patients and families make more informed decisions, ultimately leading to better outcomes for people living with neuroendocrine cancer.

 

Catch up on the latest news, stories and updates

Angela

Patient Ambassador

Angela became an Ambassador in 2026.